NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 2026-11-04 15:19இன்று 57 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Transgene Biotek: Statutory Auditor Resigns Due to Family Emergency; Successor Appointed
Transgene Biotek announced that statutory auditor M/s. Harish Gummadi & Co. resigned on November 03, 2026, citing an unforeseen family medical emergency that prevented them from completing the Q2 limited review by November 14, 2026. The auditor had been appointed just a day earlier on November 02, 2026, and confirmed no unresolved concerns or audit disagreements exist. In response, the Board approved the appointment of M/s Ranganath Prasad & Co. on November 04, 2026, to fill the casual vacancy subject to shareholder approval. The company remains financially stressed with a negative net worth of Rs -9 Cr and TTM net loss of Rs -2 Cr.
உச்சம் நம்பிக்கை
என்ன மாறியதுM/s. Harish Gummadi & Co. resigned as statutory auditor and M/s Ranganath Prasad & Co. was appointed to fill the casual vacancy.
ஏன் இது முக்கியம்Auditor transitions right around quarterly reporting deadlines can delay compliance, though the explicit personal reason and immediate replacement mitigate governance alarm.
Resignation effective date: நவம்பர் 03, 2026New auditor appointment date: நவம்பர் 04, 2026Q2 Limited Review filing deadline cited: நவம்பர் 14, 2026Previous auditor tenure: 1 day (Appointed 02-11-2026)
📅 குறுகிய காலம்Short-term focus will be on the incoming auditor's ability to review and sign off on the Q2 FY27 results before regulatory deadlines without delays.
📈 நீண்ட காலம்Limited operational impact; however, frequent changes in statutory auditors remain a monitoring point for corporate governance.
⚠ அபாய எச்சரிக்கைகள்
Auditor resignation occurred just days before the quarterly filing deadline
Pre-existing financial weakness (negative net worth of Rs -9 Cr and recurring operating losses)
👀 கவனிக்க வேண்டியவை
Track whether the new auditor completes and files the Limited Review Report for Q2 (ended September 30, 2026) within the prescribed statutory deadline, along with shareholder approval at the upcoming general meeting.
Transgene Biotek Statutory Auditor Resigns Within One Day of Appointment
Transgene Biotek announced the resignation of its statutory auditor, M/s Harish Gummadi & Co., effective November 3, 2026. The auditor was appointed on November 2, 2026, to fill a casual vacancy and resigned just one day later citing a personal medical emergency. The auditor had not issued any audit report or limited review before stepping down. This leaves the micro-cap company (market cap Rs 21 Cr, TTM revenue near Rs 0 Cr) needing to urgently appoint a new auditor to clear Q2 results due by November 14, 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுM/s Harish Gummadi & Co. resigned as statutory auditors on November 3, 2026, just one day after their appointment on November 2, 2026.
ஏன் இது முக்கியம்Abrupt auditor changes right before the quarterly earnings deadline risk compliance delays, exchange trading restrictions, and corporate governance scrutiny.
Date of appointment: 02-11-2026Date of resignation: 03-11-2026Q2 result submission deadline: 14-11-2026
📅 குறுகிய காலம்Heightened risk of delay in declaring Q2 FY27 results due by November 14, 2026, pending the onboarding of a replacement auditor.
📈 நீண்ட காலம்Frequent auditor churn in financially distressed micro-caps raises governance concerns and complicates ongoing reporting.
⚠ அபாய எச்சரிக்கைகள்
Auditor resignation after single day of appointment
Potential non-compliance with LODR Q2 financial result filing timelines
Negative net worth of Rs -9 Cr and operating losses
👀 கவனிக்க வேண்டியவை
Track the appointment of a successor statutory auditor and whether Transgene Biotek can file its Q2 FY27 results before the November 14, 2026 regulatory deadline.
Transgene Biotek Clarifies Statutory Auditor Resignation Effective 22 September 2026
Transgene Biotek has submitted additional disclosures following BSE observations regarding the resignation of its statutory auditor, M/s Vasavi & Co., Chartered Accountants (FRN: 020965S). The auditor ceased to hold office on 22nd September, 2026, citing pre-occupation with other assignments and inability to devote sufficient time. The company is financially distressed with negative net worth of ₹-9 Cr, total debt of ₹17 Cr, and TTM revenue near zero. Investors should note auditor resignations in distressed micro-caps often signal heightened governance scrutiny.
உச்சம் நம்பிக்கை
என்ன மாறியதுTransgene Biotek provided detailed disclosures to BSE regarding the resignation of M/s Vasavi & Co. as its statutory auditor, effective 22 September 2026.
ஏன் இது முக்கியம்Mid-term auditor resignations, especially in financially stressed firms (negative net worth of ₹-9 Cr and debt of ₹17 Cr), raise governance red flags and delay reporting workflows.
Date of cessation: 22nd செப்டம்பர், 2026Auditor Firm Registration Number: 020965SBSE Query Date: 30th அக்டோபர் 2026
📅 குறுகிய காலம்Watch for the formal announcement of a replacement auditor and subsequent audit sign-offs without delays.
📈 நீண்ட காலம்Structural governance risk remains elevated given the company's severe financial strain (TTM PAT of ₹-2 Cr and negative net worth).
⚠ அபாய எச்சரிக்கைகள்
Auditor resignation mid-tenure
Negative net worth of ₹-9 Cr with ₹17 Cr debt
Exchange query over disclosure non-compliance
👀 கவனிக்க வேண்டியவை
Track the appointment of the new statutory auditor and review any qualifications or emphasis of matter in the upcoming quarterly financial results.
Transgene Biotek: Newly Appointed Auditor Resigns After 18 Days Citing Family Emergency
Transgene Biotek has submitted additional disclosures regarding the resignation of statutory auditor M/s Eswara Rao & Co. with effect from October 28, 2026. The auditor was appointed on October 10, 2026 to fill a casual vacancy created by the prior resignation of M/s Vasavi & Co., lasting just 18 days in the role. The firm cited a family medical emergency that prevented partners from completing the Q2 limited review ahead of the November 14, 2026 deadline. The auditor confirmed no audit work had commenced and reported no non-cooperation or material disagreements.
உச்சம் நம்பிக்கை
என்ன மாறியதுM/s Eswara Rao & Co. stepped down as statutory auditor 18 days after being appointed to fill a previous casual vacancy.
ஏன் இது முக்கியம்Back-to-back auditor resignations raise governance and compliance overheads, risking delays in reporting financial results for a distressed company with negative net worth (Rs -9 Cr).
Date of appointment: 10 அக்டோபர் 2026Date of cessation: 28-10-2026Q2 result submission deadline cited: 14 நவம்பர் 2026Auditor tenure length: 18 நாட்கள்
📅 குறுகிய காலம்May cause reporting delays for Q2 FY27 results and requires prompt board action to fill the fresh casual vacancy.
📈 நீண்ட காலம்Repeated auditor churn points to elevated administrative instability, compounding existing operational weakness.
Potential non-compliance or delay in submitting Q2 financial results
Weak underlying financials with negative net worth of Rs -9 Cr and debt of Rs 17 Cr
👀 கவனிக்க வேண்டியவை
Track the appointment of a new statutory auditor and whether the company meets its regulatory reporting deadlines for the September 30, 2026 quarterly results.
Transgene Biotek Statutory Auditor Resigns Within 18 Days of Appointment
Transgene Biotek Ltd announced the resignation of its statutory auditor, M/s. Eswara Rao & Co., effective October 28, 2026. The firm had only been appointed on October 10, 2026, to fill a casual vacancy following the previous resignation of M/s. Vasavi & Co. The auditor cited pre-occupation with other assignments as the reason for leaving and confirmed that no audit or limited review work, including Q2 FY27 (quarter ended September 30, 2026), had commenced. This marks consecutive auditor resignations for the financially stressed micro-cap company, which has a negative net worth of ₹-9 Cr.
உச்சம் நம்பிக்கை
என்ன மாறியதுM/s. Eswara Rao & Co. stepped down as statutory auditor on October 28, 2026, having served for less than three weeks.
ஏன் இது முக்கியம்Back-to-back auditor resignations raise governance flags and threaten delays in filing quarterly financial results, particularly for a firm with negative net worth (₹-9 Cr) and zero TTM revenue.
Date of appointment: 10 அக்டோபர் 2026Date of cessation: 28-10-2026Tenure of auditor: 18 நாட்கள்Company Net Worth: Rs -9 Cr
📅 குறுகிய காலம்Potential delay in reporting Q2 financial results for the quarter ended September 30, 2026, as a replacement auditor needs to be onboarded and review the accounts.
📈 நீண்ட காலம்Persistent auditor turnover signals corporate governance instability and hampers market confidence in financial disclosures.
⚠ அபாய எச்சரிக்கைகள்
Successive statutory auditor resignations in a short span
Risk of delayed Q2 earnings filings leading to exchange scrutiny
Severe financial distress with negative net worth and operational losses
👀 கவனிக்க வேண்டியவை
Track the appointment of a new statutory auditor and the timely submission of the limited review report for the quarter ended September 30, 2026, to ensure compliance with SEBI listing timelines.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Transgene Biotek announced that its Statutory Auditors, M/s Vasavi & Co., Chartered Accountants (FRN: 020965S), have resigned with immediate effect via letter dated September 22, 2026. The auditor cited pre-occupation with other assignments and inability to devote sufficient time as the sole reason for resignation. The micro-cap company, currently reporting negative net worth of ₹-9 crore and TTM losses of ₹-2 crore, stated it will initiate steps to appoint a successor under the Companies Act, 2013.
உச்சம் நம்பிக்கை
என்ன மாறியதுM/s Vasavi & Co. has stepped down as the Statutory Auditor of Transgene Biotek effective September 22, 2026.
ஏன் இது முக்கியம்Mid-term or sudden auditor resignations are a key corporate governance monitor, particularly for financially stressed companies with negative net worth and minimal revenues.
📅 குறுகிய காலம்Likely to create negative sentiment due to corporate governance optics surrounding sudden auditor departures.
📈 நீண்ட காலம்Structural recovery hinges on finding credible auditors, resolving debt of ₹17 crore, and turning around operations from near-zero revenue.
Negative company net worth of ₹-9 Cr and debt of ₹17 Cr
Near-zero revenue generation (TTM ₹0 Cr)
👀 கவனிக்க வேண்டியவை
Track the appointment of the incoming statutory auditor and verify disclosures in the upcoming quarterly filings for any qualification or audit adjustments.
Transgene Biotek Q1 Net Loss at ₹38.9 Lakhs; Revenue Remains Minimal at ₹6 Lakhs
Transgene Biotek reported a marginal revenue of ₹6.00 Lakhs for the quarter ended June 30, 2026, compared to ₹4.95 Lakhs in the year-ago period. The company continues to be loss-making, posting a net loss of ₹38.90 Lakhs, though slightly narrowed from ₹43.37 Lakhs YoY. Finance costs of ₹28.95 Lakhs remain the largest expense head, consuming nearly five times the quarterly revenue. The company is also managing multiple legal proceedings across NCLT, SAT, and the Enforcement Directorate.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company reported its Q1 FY27 results showing continued operational stagnation and provided updates on several ongoing legal disputes and the appointment of a new internal auditor.
ஏன் இது முக்கியம்With a TTM revenue of nearly zero and a high debt-to-equity ratio of 2.05, the company's ability to service its ₹17 Cr debt and manage legal liabilities is a critical concern for solvency.
Revenue (Q1 FY27): ₹6.00 லட்சம்Net Loss (Q1 FY27): ₹38.90 லட்சம்Finance Costs: ₹28.95 லட்சம்Debt-to-Equity Ratio: 2.05Nitin Didwania Claim: ₹92.99 லட்சம்
📅 குறுகிய காலம்The stock is likely to remain volatile and under pressure given the persistent losses and the overhang of multiple legal proceedings scheduled for August and September.
📈 நீண்ட காலம்Limited; the company lacks a scalable revenue model and is burdened by high finance costs and legal liabilities that exceed its annual income.
👀 கவனிக்க வேண்டியவை
Investors should closely monitor the outcomes of the NCLT and ED hearings in September 2026, as any adverse rulings could significantly impact the company's fragile ₹8 Cr net worth.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
